Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,256 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Triptans Clear all

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Sleep Intervention, Melatonin; Behavioral · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 12 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Non-Hodgkins Lymphoma
Interventions: Cyclophosphamide, Mitoxantrone, Vincristine, Prednisone, Rituximab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 2
States / cities: Fort Myers, Florida • Nashville, Tennessee

Conditions: Lymphoma
Interventions: filgrastim, rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 6 more

Conditions: Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin
Interventions: Azacitidine with rituximab, vincristine, and cyclophosphamide; Drug
Lead sponsor: Shams Shakil; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Interventions: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Lumbar Puncture, Multigated Acquisition Scan, Venetoclax, Vincristine; Drug · Procedure · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 12 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Rhabdomyosarcoma
Interventions: Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Radiation, Bevacizumab, Sorafenib, Myeloid Growth Factor, Lymph Node Sampling, Irinotecan, Ifosfamide, Etoposide, Etoposide Phosphate, Doxorubicin, Dexrazoxane, ^1^1C-methionine; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 4
States / cities: Jacksonville, Florida • Memphis, Tennessee • Fort Worth, Texas

Conditions: Lymphoma
Interventions: Bleomycin Sulfate, Filgrastim, Cisplatin, Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride (DOX), Etoposide, Fluorouracil, Ifosfamide, Leucovorin calcium, Methotrexate, Methylprednisolone, Pentamidine, Prednisone, Trimethoprim-Sulfamethoxazole, Vincristine Sulfate, Zidovudine (AZT), Radiation Therapy; Biological · Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2005
U.S. locations: 2
States / cities: Orlando, Florida • Houston, Texas

Conditions: Malignant Melanoma
Interventions: Vincristine Sulfate Liposomes Injection; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Blindness
Interventions: Melatonin, Melatonin; Dietary Supplement · Biological
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 5 Years to 20 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate; Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 30 Years
Enrollment: 3,154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 208
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more

Conditions: Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
Interventions: denintuzumab mafodotin, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 34
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Duarte, California + 31 more

Conditions: Migraine Headache
Interventions: Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy; Drug · Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Athens, Ohio • Westerville, Ohio

Conditions: Extragonadal Germ Cell Tumor, Ovarian Cancer
Interventions: dactinomycin, filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, vincristine sulfate, conventional surgery; Biological · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Anaplastic Large Cell Lymphoma
Interventions: Cyclophosphamide, Doxorubicin hydrochloride, vincristine sulfate, prednisone, SGN-30; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions: Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography, Etoposide, Magnetic Resonance Imaging, Mosunetuzumab, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Vincristine; Procedure · Drug · Biological
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Burkitt Lymphoma, Non-Hodgkins Lymphoma, Atypical Burkitt Lymphoma
Interventions: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Methotrexate, Leucovorin, Ifosfamide, Etoposide, Cytarabine, Mesna; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Cancer, Lung Cancer, Ovarian Cancer
Interventions: Vinorelbine, XR9576; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: End Stage Renal Disease, Chronic Kidney Disease, Sleep Disorder
Interventions: Melatonin; Drug
Lead sponsor: Southeast Renal Research Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Sarcoma, Ewing, Rhabdomyosarcoma
Interventions: PEN-866, Vincristine, Temozolomide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 39 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Anorexia Nervosa
Interventions: Psilocybin, Preparation and Integration Sessions; Drug · Behavioral
Lead sponsor: Marissa Raymond-Flesch, MD, MPH; Other
Eligibility: 18 Years to 25 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Migraine Headaches
Interventions: Sumatriptan and Naproxen sodium; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Greensboro, North Carolina

Conditions: Breast Cancer, Advanced Malignant Solid Tumors
Interventions: neratinib, vinorelbine; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 8
States / cities: Fayetteville, Arkansas • Duarte, California • Lebanon, New Hampshire + 5 more

Conditions: Diffuse Large B Cell Lymphoma, DLBCL, Cancer
Interventions: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Pegfilgrastim; Drug · Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 70 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Kidney Cancer
Interventions: estramustine phosphate sodium, prednisone, vinorelbine tartrate; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: Up to 120 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Search by objective public record fields.

Improving Sleep and Daytime Functioning Among Children Diagnosed With Attention Deficit Hyperactivity Disorder (ADHD)

Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma

Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction

Blind Child Melatonin Treatment Study

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Drug and Non-Drug Treatment Of Severe Migraine

Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Vinorelbine and XR9576 to Treat Cancer

Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

Study of Psilocybin for Anorexia in Young Adults

The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months

Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

Split-Dose R-CHOP for Older Adults With DLBCL

Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer